04:57 PM EDT, 06/27/2024 (MT Newswires) -- Dynavax Technologies ( DVAX ) said late Thursday the first participant has been dosed in its phase 1/2 study of its vaccine candidate Z-1018 to prevent shingles, a disease caused by the varicella-zoster virus.

The trial, comparing Z-1018 with Shingrix, will enroll about 440 healthy adults aged 50 to 69 in Australia, the company said.

Dynavax ( DVAX ) said it expects to report top-line immunogenicity and safety data in the second half of 2025.

Price: 11.43, Change: +0.06, Percent Change: +0.53